---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-092964"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:38:47.352613+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns

## Summary
- CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.
- Phase 3 4FRONT-1 wet AMD trial topline data accelerated to H1 2027 (from H2 2027); 4FRONT-2 started in June 2025.
- Workforce reduction of ~25% of current and planned roles in July 2025, primarily early-stage R&D and support functions.
- Expected $3M in severance costs in Q3 2025; annual cash compensation savings of ~$15M.
- Cash, equivalents and marketable securities of $458M as of March 31, 2025; runway into 2028.

## SEC filing metadata
- accession: 0000950170-25-092964
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025092964/0000950170-25-092964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025092964/fdmt-20250627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-092964
- JSON: https://secwatch.observer/filing/0000950170-25-092964.json
- Plain text: https://secwatch.observer/filing/0000950170-25-092964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.